Healthcare companies by risk reading
Healthcare companies by risk reading: 1,695 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 21 October 2026.
Composite readings for 14,899 companies, recomputed 21 October 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| Straumann Holding AG STMN | 39 | Normal | Healthcare | Switzerland | 5 / 6 | $17.9B |
| Sonova H Ag SOON | 43 | Elevated | Healthcare | Switzerland | 5 / 6 | $17.9B |
| Medpace Holdings Inc MEDP | 27 | Normal | Healthcare | United States | 5 / 6 | $17.3B |
| Hologic Inc HOLX | 48 | Elevated | Healthcare | United States | 5 / 6 | $17.0B |
| Revvity Inc RVTY | 47 | Elevated | Healthcare | United States | 6 / 6 | $16.8B |
| Fisher & Paykel Healthcare Corporation Limited FPH.AX | 27 | Normal | Healthcare | New Zealand | 4 / 6 | $16.2B |
| Shionogi & Co., Ltd. 4507.T | 33 | Normal | Healthcare | Japan | 5 / 6 | $15.8B |
| JD Health International Inc. 6618.HK | 37 | Normal | Healthcare | China | 5 / 6 | $15.7B |
| Exelixis Inc EXEL | 36 | Normal | Healthcare | United States | 5 / 6 | $15.6B |
| Swedish Orphan Biovitrum AB (publ) SOBI | 31 | Normal | Healthcare | Sweden | 4 / 6 | $15.3B |
| Ascendis Pharma A/S ASND | 40 | Elevated | Healthcare | Denmark | 5 / 6 | $15.1B |
| Solventum Corp SOLV | 49 | Elevated | Healthcare | United States | 6 / 6 | $14.5B |
| Eurofins Scientific SE ERF | 45 | Elevated | Healthcare | Luxembourg | 5 / 6 | $14.4B |
| Coloplast B COLO-B.CO | 46 | Elevated | Healthcare | Denmark | 3 / 6 | $14.4B |
| Charles River Laboratories International Inc CRL | 53 | Elevated | Healthcare | United States | 5 / 6 | $14.3B |
| Halozyme Therapeutics Inc HALO | 33 | Normal | Healthcare | United States | 5 / 6 | $14.0B |
| Neurocrine Biosciences Inc NBIX | 31 | Normal | Healthcare | United States | 5 / 6 | $13.9B |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 6990.HK | 49 | Elevated | Healthcare | China | 5 / 6 | $13.8B |
| Jazz Pharmaceuticals plc JAZZ | 67 | Stretched | Healthcare | Ireland | 5 / 6 | $13.5B |
| BridgeBio Pharma Inc BBIO | 44 | Elevated | Healthcare | United States | 6 / 6 | $13.3B |
| Ipsen SA IPN | 30 | Normal | Healthcare | France | 5 / 6 | $13.2B |
| Icon Plc ICLR | 55 | Elevated | Healthcare | Ireland | 4 / 6 | $13.0B |
| Baxter International Inc BAX | 60 | Stretched | Healthcare | United States | 6 / 6 | $12.9B |
| CSPC Pharmaceutical Group Limited 1093.HK | 44 | Elevated | Healthcare | Hong Kong | 5 / 6 | $12.9B |
| Penumbra Inc PEN | 44 | Elevated | Healthcare | United States | 5 / 6 | $12.7B |
| Smith & Nephew plc SNN | 45 | Elevated | Healthcare | United Kingdom | 5 / 6 | $12.3B |
| BrightSpring Health Services Inc BTSG | 40 | Elevated | Healthcare | United States | 5 / 6 | $12.1B |
| Corcept Therapeutics Inc CORT | 35 | Normal | Healthcare | United States | 6 / 6 | $12.1B |
| Encompass Health Corp EHC | 35 | Normal | Healthcare | United States | 4 / 6 | $12.0B |
| WuXi XDC Cayman Inc. 2268.HK | 24 | Normal | Healthcare | China | 5 / 6 | $12.0B |
| Sino Biopharmaceutical Limited 1177.HK | 35 | Normal | Healthcare | Hong Kong | 5 / 6 | $11.9B |
| Elanco Animal Health Inc ELAN | 47 | Elevated | Healthcare | United States | 5 / 6 | $11.7B |
| CSPC PHARMACEUT.GR. ADR4 CVGU | 44 | Elevated | Healthcare | China | 5 / 6 | $11.7B |
| Fresenius Medical Care AG & Co. KGaA FMS | 50 | Elevated | Healthcare | Germany | 5 / 6 | $11.7B |
| Tempus AI Inc - Class A TEM | 65 | Stretched | Healthcare | United States | 4 / 6 | $11.6B |
| Olympus Corporation 7733.T | 52 | Elevated | Healthcare | Japan | 5 / 6 | $11.4B |
| Pro Medicus Limited PME.AX | 11 | Contained | Healthcare | Australia | 4 / 6 | $11.3B |
| Bio-Techne Corp TECH | 38 | Normal | Healthcare | United States | 6 / 6 | $11.3B |
| Cooper Companies Inc COO | 42 | Elevated | Healthcare | United States | 6 / 6 | $11.1B |
| Avantor Inc AVTR | 56 | Elevated | Healthcare | United States | 5 / 6 | $11.0B |
| bioMérieux S.A BIM.PA | 40 | Elevated | Healthcare | France | 6 / 6 | $11.0B |
| DaVita Inc DVA | 46 | Elevated | Healthcare | United States | 5 / 6 | $11.0B |
| Dr. Reddy`s Laboratories Ltd RDY | 47 | Elevated | Healthcare | India | 5 / 6 | $10.9B |
| Universal Health Services Inc - Class B UHS | 42 | Elevated | Healthcare | United States | 5 / 6 | $10.7B |
| Akeso, Inc. 9926.HK | 48 | Elevated | Healthcare | China | 5 / 6 | $10.7B |
| Align Technology Inc ALGN | 44 | Elevated | Healthcare | United States | 6 / 6 | $10.6B |
| Biomarin Pharmaceutical Inc BMRN | 35 | Normal | Healthcare | United States | 6 / 6 | $10.6B |
| Madrigal Pharmaceuticals Inc MDGL | 68 | Stretched | Healthcare | United States | 5 / 6 | $10.3B |
| Globus Medical Inc - Class A GMED | 40 | Elevated | Healthcare | United States | 6 / 6 | $10.2B |
| Ensign Group Inc ENSG | 46 | Elevated | Healthcare | United States | 6 / 6 | $10.1B |
| Repligen Corp RGEN | 48 | Elevated | Healthcare | United States | 5 / 6 | $10.0B |
| Demant A/S DEMANT | 45 | Elevated | Healthcare | Denmark | 5 / 6 | $9.9B |
| Insulet Corporation PODD | 39 | Normal | Healthcare | United States | 6 / 6 | $9.8B |
| Glaukos Corporation GKOS | 65 | Stretched | Healthcare | United States | 5 / 6 | $9.8B |
| Genscript Biotech Corporation 1548.HK | 36 | Normal | Healthcare | Hong Kong | 5 / 6 | $9.7B |
| Qiagen NV QGEN | 38 | Normal | Healthcare | Netherlands | 6 / 6 | $9.6B |
| Henry Schein Inc HSIC | 53 | Elevated | Healthcare | United States | 6 / 6 | $9.6B |
| Krystal Biotech Inc KRYS | 37 | Normal | Healthcare | United States | 5 / 6 | $9.5B |
| Bio-Rad Laboratories Inc - Class A BIO | 55 | Elevated | Healthcare | United States | 6 / 6 | $9.4B |
| Masimo Corp MASI | 38 | Normal | Healthcare | United States | 5 / 6 | $9.4B |
| 10x Genomics Inc - Class A TXG | 44 | Elevated | Healthcare | United States | 5 / 6 | $9.1B |
| Crinetics Pharmaceuticals Inc CRNX | 54 | Elevated | Healthcare | United States | 6 / 6 | $9.0B |
| Kymera Therapeutics Inc KYMR | 72 | Stretched | Healthcare | United States | 5 / 6 | $8.9B |
| Ramsay Health Care Ltd RHC | 51 | Elevated | Healthcare | Australia | 4 / 6 | $8.8B |
| ImmunityBio Inc IBRX | 57 | Elevated | Healthcare | United States | 6 / 6 | $8.8B |
| Eisai Co., Ltd. 4523.T | 45 | Elevated | Healthcare | Japan | 5 / 6 | $8.8B |
| Twist Bioscience Corp TWST | 40 | Elevated | Healthcare | United States | 6 / 6 | $8.8B |
| Krka d. d KRK | 43 | Elevated | Healthcare | Slovenia | 3 / 6 | $8.8B |
| Protagonist Therapeutics Inc PTGX | 50 | Elevated | Healthcare | United States | 6 / 6 | $8.7B |
| Cytokinetics Inc CYTK | 67 | Stretched | Healthcare | United States | 5 / 6 | $8.7B |
| Caris Life Sciences Inc - Class A CAI | 46 | Elevated | Healthcare | United States | 6 / 6 | $8.7B |
| RemeGen Co., Ltd. 688331.SS | 30 | Normal | Healthcare | China | 5 / 6 | $8.4B |
| Bruker Corp BRKR | 44 | Elevated | Healthcare | United States | 6 / 6 | $8.4B |
| Hinge Health Inc - Class A HNGE | 56 | Elevated | Healthcare | United States | 5 / 6 | $8.3B |
| TG Therapeutics Inc TGTX | 47 | Elevated | Healthcare | United States | 6 / 6 | $8.2B |
| Axsome Therapeutics Inc AXSM | 45 | Elevated | Healthcare | United States | 6 / 6 | $8.1B |
| Arrowhead Pharmaceuticals Inc ARWR | 20 | Normal | Healthcare | United States | 5 / 6 | $8.1B |
| Bio-Rad Laboratories Inc - Class B BIO-B | 54 | Elevated | Healthcare | United States | 6 / 6 | $8.0B |
| Aptargroup Inc ATR | 34 | Normal | Healthcare | United States | 5 / 6 | $7.9B |
| Healthequity Inc HQY | 25 | Normal | Healthcare | United States | 4 / 6 | $7.8B |
| Kyowa Kirin Co., Ltd. 4151.T | 41 | Elevated | Healthcare | Japan | 4 / 6 | $7.8B |
| ALK-Abelló A/S ALK-B | 27 | Normal | Healthcare | Denmark | 4 / 6 | $7.6B |
| Grifols S.A OZTA | 39 | Normal | Healthcare | Spain | 5 / 6 | $7.5B |
| Bachem Holding AG BANB | 44 | Elevated | Healthcare | Switzerland | 4 / 6 | $7.5B |
| M3 INC. 4YC | 29 | Normal | Healthcare | Japan | 4 / 6 | $7.4B |
| Ionis Pharmaceuticals Inc IONS | 51 | Elevated | Healthcare | United States | 5 / 6 | $7.4B |
| PACS Group Inc PACS | 41 | Elevated | Healthcare | United States | 6 / 6 | $7.3B |
| Alkermes plc ALKS | 45 | Elevated | Healthcare | Ireland | 6 / 6 | $7.2B |
| Ono Pharmaceutical Co., Ltd. 4528.T | 32 | Normal | Healthcare | Japan | 5 / 6 | $7.2B |
| Sysmex Corporation 6869.T | 46 | Elevated | Healthcare | Japan | 5 / 6 | $7.1B |
| H Lundbeck A/S HLUN-B | 30 | Normal | Healthcare | Denmark | 3 / 6 | $7.0B |
| Cidara Therapeutics Inc CDTX | 68 | Stretched | Healthcare | United States | 5 / 6 | $7.0B |
| Getinge AB ser. B GETI-B | 52 | Elevated | Healthcare | Sweden | 3 / 6 | $6.9B |
| Arcellx Inc ACLX | 60 | Stretched | Healthcare | United States | 5 / 6 | $6.7B |
| Chemed Corp CHE | 23 | Normal | Healthcare | United States | 5 / 6 | $6.6B |
| H Lundbeck A/S HLUN-A | 30 | Normal | Healthcare | Denmark | 3 / 6 | $6.6B |
| Lantheus Holdings Inc LNTH | 44 | Elevated | Healthcare | United States | 6 / 6 | $6.5B |
| Hims & Hers Health Inc - Class A HIMS | 62 | Stretched | Healthcare | United States | 5 / 6 | $6.5B |
| Sonic Healthcare Limited SHL.AX | 52 | Elevated | Healthcare | Australia | 4 / 6 | $6.5B |
| Iovance Biotherapeutics Inc IOVA | 50 | Elevated | Healthcare | United States | 6 / 6 | $6.4B |
By sector
Industrials 3,117Technology 2,425Consumer Cyclical 2,231Healthcare 1,695Consumer Defensive 1,055Basic Materials 1,055Real Estate 1,011Communication Services 956Energy 487Utilities 343Financial Services 90
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.